Evidence map›Paper›PMID 14993601›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2004

A variable dinucleotide repeat in the CFTR gene contributes to phenotype diversity by forming RNA secondary structures that alter splicing.

Timothy W Hefferon, Joshua D Groman, Catherine E Yurk, Garry R Cutting

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00037778 (Genetic Modifiers of Cystic Fibrosis), which is not on this map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00037778 completednot on this map

Genetic Modifiers of Cystic Fibrosis: Sibling Study

TypeobservationalSponsorJohns Hopkins UniversityRan2001 to 2013Enrolled3,459ConditionsLung Diseases, Cystic Fibrosis
3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 161 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Accurate and Automated Genotyping of theInternational journal of molecular sciences · 2024
    Article
  9. High frequency of germline variants in CFTR identified in PDAC patients enrolled in an expanded panel multi-gene panel testing program.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2024
    Article
  10. Article
  11. NAR genomics and bioinformatics · 2024
    Article
  12. Solution Structure of Poly(UG) RNA.Journal of molecular biology · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Timothy W HefferonMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, 600 North Wolfe Street, CMSC 9-123, Baltimore, MD 21287, USA.
Joshua D Groman
Catherine E Yurk
Garry R Cutting
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Genetic Modifiers of Cystic Fibrosis: Sibling StudyR01HL068927 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CUTTING, GARRY R · 2001 to 2011
$8.9M
MOLECULAR GENETICS OF CYSTIC FIBROSISR01DK044003 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI Garry R Cutting · 1991 to 2026
$6.7M
Molecular Genetics of Cystic FibrosisR37DK044003 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI CUTTING, GARRY R · 2003 to 2012
$3.9M
NHLBI NIH HHS HL68927NHLBI NIH HHS R01 HL068927NIDDK NIH HHS DK44003NIDDK NIH HHS R01 DK044003NIDDK NIH HHS R37 DK044003
6 · The paper itself

Abstract

Dinucleotide repeats are ubiquitous features of eukaryotic genomes that are not generally considered to have functional roles in gene expression. However, the highly variable nature of dinucleotide repeats makes them particularly interesting candidates for modifiers of RNA splicing when they are found near splicing signals. An example of a variable dinucleotide repeat that affects splicing is a TG repeat located in the splice acceptor of exon 9 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Higher repeat numbers result in reduced exon 9 splicing efficiency and, in some instances, the reduction in full-length transcript is sufficient to cause male infertility due to congenital bilateral absence of the vas deferens or nonclassic cystic fibrosis. Using a CFTR minigene system, we studied TG tract variation and observed the same correlation between dinucleotide repeat number and exon 9 splicing efficiency seen in vivo. Replacement of the TG dinucleotide tract in the minigene with random sequence abolished splicing of exon 9. Replacements of the TG tract with sequences that can self-base-pair suggested that the formation of an RNA secondary structure was associated with efficient splicing. However, splicing efficiency was inversely correlated with the predicted thermodynamic stability of such structures, demonstrating that intermediate stability was optimal. Finally, substitution with TA repeats of differing length confirmed that stability of the RNA secondary structure, not sequence content, correlated with splicing efficiency. Taken together, these data indicate that dinucleotide repeats can form secondary structures that have variable effects on RNA splicing efficiency and clinical phenotype.

Indexed as

Dinucleotide RepeatsBase SequenceCell LineCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDNA, ComplementaryExonsHumansMaleMutagenesis, Site-DirectedNucleic Acid ConformationPhenotypeRNARNA SplicingRNA StabilityThermodynamicsCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorDNA, ComplementaryRNA

Identifiers

PMID14993601
PMCPMC373492
OpenAlexW2001169216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.